---
layout: default
title: Ropeginterferon Alfa-2B
parent: Low Evidence (L4-L5)
nav_order: 603
evidence_level: L5
indication_count: 10
---

# Ropeginterferon Alfa-2B
{: .fs-9 }

Tahap bukti: **L5** | Indikasi diramal: **10** 
{: .fs-6 .fw-300 }

---

## Isi kandungan
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Laporan penilaian ahli farmasi

</div>

# Ropeginterferon Alfa-2b: From Polycythemia Vera to Laubry-Pezzi Syndrome (Prediction Not Supported)

## One-Sentence Summary

Ropeginterferon alfa-2b (DrugBank DB15119) is marketed in Malaysia with 1 registered license, but its approved indication text is not available in the current dataset — external evidence embedded in this pack's own literature (see Rank 6 below) points to Polycythemia Vera (brand Besremi) as the established use. The TxGNN model's top prediction, **Laubry-Pezzi syndrome**, is a structural congenital heart defect with **zero clinical trials, zero literature, and no biologically plausible mechanistic link** to interferon pharmacology — this and all 9 other top-10 candidates are flagged in the evidence pack itself as likely embedding-space noise or disease-ontology mapping errors.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in Malaysia registration data (approved_indication_text is blank); literature context suggests Polycythemia Vera (see note below) |
| Predicted New Indication | Laubry-Pezzi syndrome |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available (`original_moa: [Data Gap]`). Ropeginterferon alfa-2b is a pegylated interferon alfa-2b, a class generally understood to act via immunomodulatory, antiviral, and antiproliferative (JAK-STAT-mediated) pathways.

The top-ranked prediction, Laubry-Pezzi syndrome, is a structural congenital cardiac malformation (ventricular septal defect with aortic valve prolapse/aneurysm). There is no plausible biological pathway connecting an interferon's immune/antiproliferative mechanism to a structural anatomical defect, and the evidence pack's own rationale explicitly characterizes this as "high-score noise in the KG embedding space" with zero supporting trials or publications. The remaining ranks 2–10 (interventricular septum aneurysm, chromosomal deletion syndromes, craniofacial malformation syndromes, pulmonary valve disease) share the same pattern: high TxGNN scores with no mechanistic or evidentiary support.

Notably, Rank 6 ("disorder of fucoglycosan synthesis") returned 4 literature hits, but all 4 papers concern ropeginterferon alfa-2b in **Polycythemia Vera** — unrelated to the disease label attached to that rank. This strongly suggests a disease-ontology mapping error in the underlying knowledge graph, and incidentally indicates that Polycythemia Vera is the drug's actual established indication (matching its approved brand, Besremi), not a new repurposing candidate.

## Clinical Trial Evidence

Currently no related clinical trials registered for Laubry-Pezzi syndrome.

## Literature Evidence

Currently no related literature available for Laubry-Pezzi syndrome.

## Malaysia Market Information

Malaysia has 1 registered license for ropeginterferon alfa-2b (market status: Marketed), but the license number, product name, dosage form, and approved indication text are not populated in the current dataset.

## Safety Considerations

Please refer to the package insert for safety information. (Key warnings and contraindications are flagged as a **Blocking** data gap — DG001 — pending retrieval of the NPRA/TFDA product insert; this must be resolved before any safety review can proceed.)

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
None of the top 10 TxGNN predictions — including the top-ranked Laubry-Pezzi syndrome — have any supporting clinical trials, literature, or mechanistic plausibility. The evidence pack itself flags these as likely embedding-space noise, and one candidate (Rank 6) reveals an apparent disease-ontology mapping error rather than genuine repurposing signal.

**To proceed, the following is needed:**
- Resolve the DG001 blocking gap: retrieve NPRA product insert (warnings/contraindications) for safety screening
- Resolve the DG002 gap: obtain confirmed mechanism of action from DrugBank
- Correct the disease-ontology mapping error affecting the "disorder of fucoglycosan synthesis" label (Rank 6), which appears to actually reference Polycythemia Vera literature
- Confirm the drug's true original approved indication via NPRA license text (currently blank) rather than inference
- Re-run prediction review beyond the top 10 ranks, since none in this set meet even L4 (preclinical/mechanistic) evidence thresholds
## Penafian

Kandungan ini adalah untuk tujuan penyelidikan sahaja dan bukan nasihat perubatan.
Pengesahan klinikal diperlukan sebelum sebarang aplikasi klinikal.

---

